The mechanism of and the association between interleukin‑27 and chemotherapeutic drug sensitivity in lung cancer

Abstract

Interleukins (ILs) are involved in the occurrence and development of numerous types of cancer, and serve a critical role in the development of effective cancer therapeutics. The aim of the present study was to investigate the effect of IL-27 on chemotherapy resistance in lung cancer cells, and analyze its potential molecular mechanism in lung cancer tissues. Western blot analysis and reverse transcription-quantitative polymerase chain reaction were performed to examine the RNA and protein expression levels of IL-27. A Cell Counting Kit-8 assay was performed to evaluate the proliferation rates of the lung cancer line A549. Flow cytometry was subsequently applied to determine the rate of apoptosis in A549 cells. The data obtained revealed that the expression of IL-27 with cisplatin, significantly suppressed the proliferation and apoptosis of A549 cells compared with that in the cisplatin treatment group alone. The expression of Akt and apoptosis factors such as Caspase-3 and Bcl-2/Bax also ascertained that upregulated IL-27 inhibited the development of cancer and increased apoptosis in the A549 cells. Therefore, IL-27 may represent a potential target for antitumor therapy, especially when considering the clinical challenges presented by the development of chemoresistance in tumors. These findings suggest that IL-27 is a promising biomarker and represents a novel treatment strategy for patients with lung cancer.

The Role of the IL-6 Cytokine Family in Epithelial–Mesenchymal Plasticity in Cancer Progression

“…Interleukin-27 (IL-27), which also belongs to the IL-12 family, has been described as a potential anti-tumour therapeutic agent [ 154 , 155 ]. Surprisingly, independent pro-tumorigenic effects have been attributed to the IL-27/p28 subunit or IL-30 cytokine in prostate and breast cancers, which have been recently reviewed [ 156 , 157 ].…”

Activation of the TGF-β Pathway Enhances the Efficacy of Platinum-Based Chemotherapy in Small Cell Lung Cancer Patients

“…Moreover, patients with high TNFSF10 expression usually exhibited a response to chemotherapy [41], while TNFRSF4 was associated with chemosensitivity and good prognosis in ovarian cancer patients [42], and IRF7 was upregulated in patients in the chemotherapy responsive group [43]. IL-7, IL-12, and IL-27 signaling pathways were highly activated in the TGFB-HIGH group, and studies have shown that they can enhance the antitumor response of chemotherapeutic drugs [44][45][46]. Thus, a high activation status of the TGFB pathway Disease Markers may improve the response to chemotherapy in SCLC patients by affecting the expression of immune-related genes.…”

Supramolecular Chemotherapy: Host–Guest Complexes of Heptaplatin-Cucurbit[7]uril toward Colorectal Normal and Tumor Cells

“…Platinum-derived antitumor agents can induce apoptosis of tumor cells. 35,36 How about heptaplatin-CB [7]? Significant changes in colorectal tumor cell apoptosis were obtained after 4 h of exposure between treatment by the control and 50.0 μM heptaplatin-CB [7] (molar ratio = 1:1) and heptaplatin (Figure 6 and Figure S7).…”